Nonalcoholic Fatty Liver Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762
Younossi, 2015, Global epidemiology of nonalcoholic fatty liver disease–Meta-analytic assessment of prevalence, incidence and outcomes, Hepatology, 64, 73, 10.1002/hep.28431
Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x
Petersen, 2006, Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men, Proc Natl Acad Sci U S A, 103, 18273, 10.1073/pnas.0608537103
Pan, 2014, Gender and racial differences in nonalcoholic fatty liver disease, World J Hepatol, 6, 274, 10.4254/wjh.v6.i5.274
Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466
Fleischman, 2014, NAFLD prevalence differs among Hispanic subgroups: the multi-ethnic study of atherosclerosis, World J Gastroenterol, 20, 4987, 10.3748/wjg.v20.i17.4987
Kallwitz, 2015, Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage, Clin Gastroenterol Hepatol, 13, 569, 10.1016/j.cgh.2014.08.037
Saab, 2016, Nonalcoholic fatty liver disease in Latinos, Clin Gastroenterol Hepatol, 14, 5, 10.1016/j.cgh.2015.05.001
Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061
Rafiq, 2009, Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016/j.cgh.2008.11.005
Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404
Liu, 2006, Ethnic-specific criteria for the metabolic syndrome: evidence from china, Diabetes Care, 29, 1414, 10.2337/dc06-0481
Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161
Lonardo, 2015, Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome, Dig Liver Dis, 47, 181, 10.1016/j.dld.2014.09.020
Pelchat, 2004, Images of desire: food-craving activation during fMRI, Neuroimage, 23, 1486, 10.1016/j.neuroimage.2004.08.023
Kelley, 2002, Opioid modulation of taste hedonics within the ventral striatum, Physiol Behav, 76, 365, 10.1016/S0031-9384(02)00751-5
Page, 2013, Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways, JAMA, 309, 63, 10.1001/jama.2012.116975
Teff, 2004, Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women, J Clin Endocrinol Metab, 89, 2963, 10.1210/jc.2003-031855
Buechler, 2011, Adiponectin, a key adipokine in obesity related liver diseases, World J Gastroenterol, 17, 2801
Chitturi, 2002, Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?, Hepatology, 36, 403, 10.1053/jhep.2002.34738
Targher, 2006, Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease, Clin Endocrinol (Oxf), 64, 679, 10.1111/j.1365-2265.2006.02527.x
Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X
Kang, 2006, Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD, Am J Gastroenterol, 101, 2247, 10.1111/j.1572-0241.2006.00719.x
Musso, 2003, Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis, Hepatology, 37, 909, 10.1053/jhep.2003.50132
Lai, 2005, Effects of a high-fiber diet on hepatocyte apoptosis and liver regeneration after partial hepatectomy in rats with fatty liver, JPEN J Parenter Enteral Nutr, 29, 401, 10.1177/0148607105029006401
Sullivan, 2010, Implications of diet on nonalcoholic fatty liver disease, Curr Opin Gastroenterol, 26, 160, 10.1097/MOG.0b013e3283358a58
Festi, 2014, Gut microbiota and metabolic syndrome, World J Gastroenterol, 20, 16079, 10.3748/wjg.v20.i43.16079
Ouyang, 2008, Fructose consumption as a risk factor for non-alcoholic fatty liver disease, J Hepatol, 48, 993, 10.1016/j.jhep.2008.02.011
Abid, 2009, Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome, J Hepatol, 51, 918, 10.1016/j.jhep.2009.05.033
Mouzaki, 2013, Intestinal microbiota in patients with nonalcoholic fatty liver disease, Hepatology, 58, 120, 10.1002/hep.26319
Miele, 2009, Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease, Hepatology, 49, 1877, 10.1002/hep.22848
Giorgio, 2014, Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity, Dig Liver Dis, 46, 556, 10.1016/j.dld.2014.02.010
Fu, 2013, Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes, Curr Diabetes Rev, 9, 25, 10.2174/157339913804143225
McGarry, 1992, What if Minkowski had been ageusic? An alternative angle on diabetes, Science, 258, 766, 10.1126/science.1439783
Gao, 2016, Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?, Gastroenterology, 150, 1704, 10.1053/j.gastro.2016.01.025
Makkonen, 2009, Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins, J Hepatol, 50, 1035, 10.1016/j.jhep.2008.12.025
Jenkins, 2004, Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase a2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities, J Biol Chem, 279, 48968, 10.1074/jbc.M407841200
He, 2010, A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis, J Biol Chem, 285, 6706, 10.1074/jbc.M109.064501
Speliotes, 2010, PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease, Hepatology, 52, 904, 10.1002/hep.23768
Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257
Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283
Santoro, 2010, A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents, Hepatology, 52, 1281, 10.1002/hep.23832
Hernaez, 2013, Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey, Clin Gastroenterol Hepatol, 11, 1183, 10.1016/j.cgh.2013.02.011
Basantani, 2011, PNPLA3/adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome, J Lipid Res, 52, 318, 10.1194/jlr.M011205
Li, 2012, Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis, J Clin Invest, 122, 4130, 10.1172/JCI65179
Smagris, 2015, PNPLA3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis, Hepatology, 61, 108, 10.1002/hep.27242
Speliotes, 2011, Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, PLoS Genet, 7, e1001324, 10.1371/journal.pgen.1001324
Palmer, 2013, Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent, Hepatology, 58, 966, 10.1002/hep.26440
Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429
Verma, 2013, Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD), Liver Int, 33, 1398, 10.1111/liv.12226
Adams, 2004, The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 99, 1316, 10.1111/j.1572-0241.2004.30444.x
Cotler, 2004, Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis, J Clin Gastroenterol, 38, 801, 10.1097/01.mcg.0000139072.38580.a0
Loria, 2003, Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates, Dig Dis Sci, 48, 2173, 10.1023/B:DDAS.0000004522.36120.08
Lee, 2010, Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations, J Hepatol, 52, 579, 10.1016/j.jhep.2010.01.008
Saadeh, 2002, The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 123, 745, 10.1053/gast.2002.35354
Feldstein, 2009, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study, Hepatology, 50, 1072, 10.1002/hep.23050
Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496
Castera, 2010, Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations, Hepatology, 51, 828
Rinaldi, 2014, Hepatic steatosis and necro-inflammatory activity overestimate liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis c, J Hepat Res, 1, 1012
Myers, 2012, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624
Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048
Booth, 2004, Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status, Am J Clin Nutr, 80, 143, 10.1093/ajcn/80.1.143
Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043
Carr, 2016, Pathophysiology of lipid droplet proteins in liver diseases, Exp Cell Res, 340, 187, 10.1016/j.yexcr.2015.10.021
Straub, 2013, Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation, Histopathology, 62, 617, 10.1111/his.12038
Straub, 2008, Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis, Hepatology, 47, 1936, 10.1002/hep.22268
Carr, 2012, Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice, Am J Physiol Regul Integr Comp Physiol, 302, R996, 10.1152/ajpregu.00177.2011
Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701
Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084
Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276
Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005
Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734
Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326
Chalasani, 2009, Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design, Contemp Clin Trials, 30, 88, 10.1016/j.cct.2008.09.003
Carr, 2015, FXR agonists as therapeutic agents for non-alcoholic fatty liver disease, Curr Atheroscler Rep, 17, 500, 10.1007/s11883-015-0500-2
Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4
Clinical trials.Gov. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02548351.
Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038
Lassailly, 2015, Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients, Gastroenterology, 149, 379, 10.1053/j.gastro.2015.04.014
Abu Dayyeh, 2015, Endoscopic bariatric therapies, Gastrointest Endosc, 81, 1073, 10.1016/j.gie.2015.02.023
Gorden, 2013, Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity, Hum Hered, 75, 34, 10.1159/000346195